Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

John F. DiPersio, MD, PhD, Ivana NM Micallef, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 1136.

https://doi.org/10.1182/blood.V112.11.1136.1136

Published: 2008

Journal Articles

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

John F. DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, Ivana NM Micallef, MD, Patrick J. Stiff, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 3312.

https://doi.org/10.1182/blood.V112.11.3312.3312

Published: 2008

Journal Articles

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Patrick J. Stiff, MD, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, MD, Richard Thomas Maziarz, MD, Brian J. Bolwell, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Jennifer Angell, MS, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 2175.

https://doi.org/10.1182/blood.V112.11.2175.2175

Published: 2008

Journal Articles

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

Ivana Micallef, MD, Patrick J. Stiff, MD, John F. DiPersio, MD, PhD, Richard Thomas Maziarz, MD, John M. McCarty, MD, Jennifer Angell, MS, Gary Bridger, PhD, Gary Calandra, MD, on behalf of the 3101 Investigators7

Blood (2007) 110 (11): 602.

https://doi.org/10.1182/blood.V110.11.602.602

Published: 2007

Journal Articles

The CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GROβ Synergistically Mobilize Hematopoetic Stem Cells (HSC) with Short and Long Term Repopulating Activity.

Louis M. Pelus, PhD, Seiji Fukuda, MD, PhD, Gary Bridger, PhD

Blood (2006) 108 (11): 339.

https://doi.org/10.1182/blood.V108.11.339.339

Published: 2006

Journal Articles

Suprasynergistic Peripheral Blood Stem Cell Mobilization in Normal and Fanconi Anemia Knockout Mice by the Combination of G-CSF Plus the CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GRO β

Louis M. Pelus, PhD, D. Wade Clapp, MD, Gary Bridger, PhD

Blood (2006) 108 (11): 3185.

https://doi.org/10.1182/blood.V108.11.3185.3185

Published: 2006

Journal Articles

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Steven M. Devine, MD, Ravi Vij, MD, Laura Todt, RN, Kiley McLaughlin, BS, Nicholas Fisher, BA, Natalie Morris, Daniel C. Link, MD, Gary Calandra, MD, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2006) 108 (11): 53.

https://doi.org/10.1182/blood.V108.11.53.53

Published: 2006

Journal Articles

CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.

Bruno Nervi, MD, Pablo Ramirez, MD, Matthew Holt, Michael P. Rettig, PhD, Julie K. Ritchey, Julie L. Prior, David Piwnica-Worms, MD,PhD, Gary Bridger, PhD, Timothy J. Ley, MD,PhD, John F. DiPersio, MD,PhD

Blood (2006) 108 (11): 569.

https://doi.org/10.1182/blood.V108.11.569.569

Published: 2006

Journal Articles

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Michael Rettig, PhD, Matthew Holt, Fulu Liu, MD, Julie Ritchey, Daniel Link, MD, Gary Bridger, PhD, John DiPersio, MD/PhD

Blood (2005) 106 (11): 5224.

https://doi.org/10.1182/blood.V106.11.5224.5224

Published: 2005

Journal Articles

Mobilization as a Preparative Regimen for Hematopoietic Stem Cell (HSC) Transplantation in Rhesus Macaques.

Andre Larochelle, MD, PhD, Cynthia L. Perez, MSc, Allen Krouse, Mark Metzger, Simon Fricker, PhD, Gary Bridger, PhD, Donald Orlic, MD, Robert E. Donahue, DVM, Janis L. Abkowitz, MD, Cynthia E. Dunbar, MD

Blood (2005) 106 (11): 1709.

https://doi.org/10.1182/blood.V106.11.1709.1709

Published: 2005

Journal Articles

Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.

Bill Q. Gai, MD, PhD, Matthew S. Holt, Bruno Nervi, MD, Michael P. Rettig, PhD, Julie K. Ritchey, Gary Bridger, PhD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 5217.

https://doi.org/10.1182/blood.V106.11.5217.5217

Published: 2005

Journal Articles

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

Timon Seeger, Patrick Maier, PhD, Li Li, PhD, Stephanie Laufs, PhD, Volker Eckstein, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Frederik Wenz, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 4264.

https://doi.org/10.1182/blood.V106.11.4264.4264

Published: 2005

Journal Articles

AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).

Joseph McGuirk, MD, John McCarty, MD, Kaaren Gibb, BSc, Karin Badel, BSc, N Gary Bridger, PhD, Gary Calandra, PhD, MD

Blood (2005) 106 (11): 154.

https://doi.org/10.1182/blood.V106.11.154.154

Published: 2005

Journal Articles

Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML.

Zhihong Zeng, MD, Marina Konopleva, MD, PhD, Billie J. Nowak, BS, William Plunkett, PhD, Gautam Borthakur, MD, Elihu Estey, MD, Richard Champlin, MD, Gary Bridger, PhD, Michael Andreeff, MD, PhD

Blood (2005) 106 (11): 474.

https://doi.org/10.1182/blood.V106.11.474.474

Published: 2005

Journal Articles

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Timon Seeger, Marlon Veldwijk, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Hartmut Goldschmidt, MD, Anthony Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 1969.

https://doi.org/10.1182/blood.V106.11.1969.1969

Published: 2005

Journal Articles

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

Steven M. Devine, MD, Leslie Andritsos, MD, Laura Todt, Ravi Vij, MD, Jesper Bonde, PhD, David Hess, PhD, Jan Nolta, PhD, Dan Link, MD, Gary Bridger, PhD, Gary Calandra, MD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 299.

https://doi.org/10.1182/blood.V106.11.299.299

Published: 2005

Journal Articles

AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.

Bruno Nervi, MD, Matthew Holt, Michael P. Rettig, PhD, Gary Bridger, PhD, Timothy J. Ley, MD, PhD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 246.

https://doi.org/10.1182/blood.V106.11.246.246

Published: 2005

NARROW

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

The CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GROβ Synergistically Mobilize Hematopoetic Stem Cells (HSC) with Short and Long Term Repopulating Activity.

Suprasynergistic Peripheral Blood Stem Cell Mobilization in Normal and Fanconi Anemia Knockout Mice by the Combination of G-CSF Plus the CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GRO β

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Mobilization as a Preparative Regimen for Hematopoietic Stem Cell (HSC) Transplantation in Rhesus Macaques.

Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

AMD3100 Plus G-CSF Use in Proven Poor Mobilizers in a Compassionate Use Protocol (CUP).

Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML.

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.

AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only